Spyre Therapeutics Statistics
Total Valuation
SYRE has a market cap or net worth of $1.08 billion. The enterprise value is $477.92 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SYRE has 60.26 million shares outstanding. The number of shares has increased by 581.85% in one year.
Current Share Class | 60.26M |
Shares Outstanding | 60.26M |
Shares Change (YoY) | +581.85% |
Shares Change (QoQ) | +8.59% |
Owned by Insiders (%) | 8.74% |
Owned by Institutions (%) | 87.31% |
Float | 46.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.99 |
P/TBV Ratio | 2.99 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.26
Current Ratio | 11.26 |
Quick Ratio | 11.16 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.28% and return on invested capital (ROIC) is -37.15%.
Return on Equity (ROE) | -59.28% |
Return on Assets (ROA) | -27.43% |
Return on Invested Capital (ROIC) | -37.15% |
Return on Capital Employed (ROCE) | -37.62% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.30M |
Employee Count | 65 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, SYRE has paid $51,000 in taxes.
Income Tax | 51,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.51% in the last 52 weeks. The beta is 2.99, so SYRE's price volatility has been higher than the market average.
Beta (5Y) | 2.99 |
52-Week Price Change | -51.51% |
50-Day Moving Average | 20.50 |
200-Day Moving Average | 26.24 |
Relative Strength Index (RSI) | 43.06 |
Average Volume (20 Days) | 663,141 |
Short Selling Information
The latest short interest is 10.77 million, so 17.87% of the outstanding shares have been sold short.
Short Interest | 10.77M |
Short Previous Month | 10.02M |
Short % of Shares Out | 17.87% |
Short % of Float | 23.11% |
Short Ratio (days to cover) | 16.54 |
Income Statement
Revenue | n/a |
Gross Profit | -162.79M |
Operating Income | -208.57M |
Pretax Income | -185.95M |
Net Income | -149.56M |
EBITDA | -207.82M |
EBIT | -208.57M |
Earnings Per Share (EPS) | -$3.18 |
Full Income Statement Balance Sheet
The company has $603.09 million in cash and n/a in debt, giving a net cash position of $603.09 million or $10.01 per share.
Cash & Cash Equivalents | 603.09M |
Total Debt | n/a |
Net Cash | 603.09M |
Net Cash Per Share | $10.01 |
Equity (Book Value) | 517.80M |
Book Value Per Share | 6.01 |
Working Capital | 554.41M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -157.41M |
Capital Expenditures | n/a |
Free Cash Flow | -157.41M |
FCF Per Share | -$2.61 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SYRE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -581.85% |
Shareholder Yield | n/a |
Earnings Yield | -13.83% |
FCF Yield | -14.56% |
Analyst Forecast
The average price target for SYRE is $51.50, which is 187.07% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $51.50 |
Price Target Difference | 187.07% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 8.65% |
Stock Forecasts Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.04:1.
Last Split Date | Sep 8, 2023 |
Split Type | Reverse |
Split Ratio | 0.04:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |